EGFR and neoplasm: First-line sensitivity to EGFR-TKIs in NSCLC has been associated with pre-existent AKT activation, and EGFR-TKIs fail to block AKT signaling in tumor cells that are intrinsically or extrinsically resistant to these drugs [7–9].